individual tumor, within an individual patient (particularly between the primary tumor and lktastatic lesions), among the subtypes of a specific type of cancer, or within cancers that originate from diklerent tissues. Because of the potential for immunity (either the natural immune system or via immunotherapeutics) to halt the progression of consensus, given that existing data to support evidence-based recommendations are limited. Conclusion: The TRIO recommendations are intended to improve the reporting of IO clinical trials and thus provide more complete evidence on the relative benefits and risks of an IO therapeutic approach. Given the rapid expansion of the number of IO clinical trials and ongoing
individual tumor, within an individual patient (particularly between the primary tumor and lktastatic lesions), among the subtypes of a specific type of cancer, or within cancers that originate from diklerent tissues. Because of the potential for immunity (either the natural immune system or via immunotherapeutics) to halt the progression of